{"SARS-CoV-2": [0, 55, 156, 212], "has": [1], "caused": [2], "tens": [3], "of": [4, 6, 25, 29, 43, 86, 106, 113, 139, 161, 191], "thousands": [5], "infections": [7], "and": [8, 67, 102, 110, 126, 151, 164, 181, 187, 202], "more": [9], "than": [10], "one": [11], "thousand": [12], "deaths.": [13], "There": [14], "are": [15], "currently": [16, 147, 198], "no": [17], "registered": [18], "therapies": [19], "for": [20, 155, 183, 195, 207], "treating": [21], "coronavirus": [22], "infections.": [23, 213], "Because": [24], "time": [26], "consuming": [27], "process": [28], "new": [30, 178, 193, 205], "drug": [31, 33, 100, 208], "development,": [32], "repositioning": [34, 209], "may": [35], "be": [36, 73], "the": [37, 41, 51, 149], "only": [38], "solution": [39], "to": [40, 210], "epidemic": [42], "sudden": [44], "infectious": [45], "diseases.": [46], "We": [47], "systematically": [48], "analyzed": [49], "all": [50], "proteins": [52, 60], "encoded": [53], "by": [54, 75], "genes,": [56], "compared": [57], "them": [58], "with": [59], "from": [61], "other": [62], "coronaviruses,": [63], "predicted": [64], "their": [65], "structures,": [66], "built": [68], "19": [69], "structures": [70], "that": [71], "could": [72], "done": [74], "homology": [76], "modeling.": [77], "By": [78], "performing": [79], "target-based": [80], "virtual": [81], "ligand": [82], "screening,": [83], "a": [84, 137, 169], "total": [85], "21": [87], "targets": [88, 115, 160, 182], "(including": [89], "two": [90], "human": [91], "targets)": [92], "were": [93, 131, 172], "screened": [94], "against": [95], "compound": [96], "libraries": [97], "including": [98, 145], "ZINC": [99], "database": [101, 105, 138], "our": [103], "own": [104], "natural": [107], "products.": [108], "Structure": [109], "screening": [111], "results": [112], "important": [114], "such": [116], "as": [117], "3-chymotrypsin-like": [118], "protease": [119, 129], "(3CLpro),": [120], "Spike,": [121], "RNA-dependent": [122], "RNA": [123], "polymerase": [124], "(RdRp),": [125], "papain": [127], "like": [128], "(PLpro)": [130], "discussed": [132], "in": [133, 185, 188], "detail.": [134], "In": [135], "addition,": [136], "78": [140], "commonly": [141], "used": [142], "anti-viral": [143], "drugs": [144, 166, 197], "those": [146, 196], "on": [148, 168], "market": [150], "undergoing": [152], "clinical": [153, 200], "trials": [154], "was": [157], "constructed.": [158], "Possible": [159], "these": [162], "compounds": [163, 180], "potential": [165], "acting": [167], "certain": [170], "target": [171], "predicted.": [173], "This": [174], "study": [175], "will": [176], "provide": [177], "lead": [179], "further": [184], "vitro": [186], "vivo": [189], "studies": [190], "SARS-CoV-2,": [192], "insights": [194], "ongoing": [199], "studies,": [201], "also": [203], "possible": [204], "strategies": [206], "treat": [211]}